ISSN 2407-2230 | E-ISSN 1907-3062 | Universa Medicina content is searchable on DOAJ, Google Scholar, and OAI

Type IV collagen as marker of fibrosis in nonalcoholic liver disease

Alvina Alvina
Submission date: Wednesday, 24 February 2016
Published date: Friday, 26 February 2016
DOI: http://dx.doi.org/10.18051/UnivMed.2010.v29.114-122

Abstract


Currently nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) are medical problems associated with the increasing prevalence of diabetes mellitus, obesity, hypertension and hypertriglyceridemia, usually designated as the metabolic syndrome associated with insulin resistance. One study demonstrated an increase in NAFLD prevalence of around 17-33% and in NASH prevalence of 5.7-16.5%. NAFLD comprises a range of mild to severe conditions, from simple steatosis to steatohepatitis, hepatic fibrosis and cirrhosis. The diagnosis of hepatic fibrosis is important for prognosis, stratification for treatment, and monitoring of treatment efficacy. Ultrasonography (USG) is a simple method for detecting fatty infiltrates in the liver. USG has a sensitivity of 82-89% and a specificity of 93%, but cannot differentiate between hepatic steatosis and fibrosis. The gold standard for evaluation of hepatic fibrosis is liver biopsy, which however is a painful and invasive procedure. Currently determination of serum type IV collagen has been suggested as an alternative to liver biopsy among the non-invasive methods for evaluation of hepatic fibrosis, as its serum concentration is closely correlated with advanced hepatic fibrosis in NASH. Type IV collagen is one of the components of basement membrane and its serum concentration is indicative of degradation of the extracellular matrix.

Keywords


NAFLD; NASH; type IV collagen; hepatic fibrosis

Full Text:

PDF

References


Das SK, Mukherjee S, Vasudevan D. Nonalcoholic fatty liver disease: an underrecognized cause with emerging importance. Current Science 2006;90:659-65.

Basaranoglu M, Neuschwander-Tetri BA. Nonalcoholic fatty liver disease: clinical features and pathogenesis. Gastroenterol Hepatol 2006;2: 282-9.

Amarapurkar D. How common is NAFLD in Asia Pacific and is there local differences. The Consensus on NAFLD/NASH. Cebu; 2006.

Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 2002;346:1221-31.

Bayard M, Holt J, Boroughs E. Nonalcoholic fatty liver disease. Am Fam Physician 2006;73:1961-8.

Lupsor M, Badea R. Imaging diagnosis and quantification of hepatic steatosis: is it an accepted alternative to needle biopsy? Rom J Gastroenterol 2005;14:419-25.

Farrell GC, Larter CZ. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology 2006;43:S99-112.

Gani RA. Manifestasi klinik dan penatalaksanaan nonalcoholic fatty liver disease (NAFLD). Jakarta: Ilmu Penyakit Dalam FKUI; 2002.

Lesmana LA. Penyakit perlemakan hati nonalkoholik. Dalam: Sulaiman A, Akbar N, Lesmana LA, Noer S, editors. Buku Ajar Ilmu Penyakit Hati. ed 1. Jakarta: Jayabadi; 2007.p. 301-5.

Adams LA, Angulo P, Lindor KD. Nonalcoholic fatty liver disease. JAMC 2005;172:899-905.

McAvoy N, Ferguson J, Campbell I, Hayes P. Nonalcoholic fatty liver disease: natural history, pathogenesis, and treatment. Br J Diabetes Vasc Dis 2006;6:251-60.

McAvoy N, Lockman A, Hayes P. Nonalcoholic fatty liver disease (NAFLD): an overview. J R Coll Physicians Edinb 2007;37:9-17.

Olufadi R, Byrne C. Clinical and laboratory diagnosis of the metabolic syndrome J Clin Pathol 2008;61:697-706.

Oneta CM, Dufour JF. Nonalcoholic fatty liver disease: treatment options based on pathogenic considerations. Swiss Med Wkly 2002;132:493-505.

Feldstein A, Werneburg N, Canbay A, Guicciardi M, Bronk S, Rydzewski R. Free fatty acids promote hepatic lipotoxicity by stimulating TNF-alpha expression via a lysosomal pathway. Hepatology 2004;40:185-94.

Bataller R, Brenner DA. Liver fibrosis. J Clin Invest 2005;115:209-18.

Tiniakos D, Kittas C. Pathology of nonalcoholic fatty liver disease. Ann Gastroenterol 2005;18: 148-59.

Tetri BAN. Fatty liver and nonalcoholic steatohepatitis. Liver Dis 2001;3:47-54.

Grigorescu M. Noninvasive biochemical markers of liver fibrosis. J Gastrointestin Liver Dis 2006;15:149-59.

Browning JD, Horton JD. Molecular mediators of hepatic steatosis and liver injury. J Clin Invest 2004;114:147-52.

Afdhal NH. Biopsy or biomarkers: is there a gold standard for diagnosis of liver fibrosis? Clin Chem 2004;50:1299-300.

Cadranel JF, Rufat P, Degos F. Practices of liver biopsy in France: results of a prospective nationwide survey. For the Group of Epidemiology of the French Association for the Study of the Liver (AFEF). Hepatology 2000;32: 477–81.

Ratziu V, Charlotte F, Heurtier A. Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology 2005;128:1898–906.

Scheuer PJ. Assessment of liver biopsies in chronic hepatitis: how is it best done? J Hepatol 2003;38:240–2.

Rosenberg WM. Rating fibrosis progression in chronic liver diseases. J Hepatol 2003;38:357–60.

King MW. The extracellular matrix. Available at: http://www.making@medicine.indstate.edu. Accessed April 2, 2010.

Guha IN, Parkes J, Roderick PR, Harris S, Rosenberg WM. Non-invasive markers associated with liver fibrosis in non-alcoholic fatty liver disease. Gut 2006;55:1650–60.

Carey E, Carey WD. Noninvasive tests for liver disease, fibrosis, and cirrhosis: is liver biopsy obsolete? Cleveland Clinic J Medicine 2010;77: 519-27.

Insert package for determination of human type IV collagen in serum panassay IV C (Latex). Daichi. 2008

Kalluri R. Basement membranes: structure, assembly, and role in tumour angiogenesis. Nat Rev Cancer 2003;3:422-33.

Yoneda M, Mawatari H, Fujita K, Yonemitsu K, Kato S, Takahashi H. Type IV collagen 7S domain is an independent clinical marker of the severity of fibrosis in patients with nonalcoholic steatohepatitis before the cirrhotic stage. J Gastroenterol 2007:375-81.

Kubo S, Tsukamoto T, Hirohashi K, Tanaka H, Shuto T, Takemura S. Correlation between preoperative serum concentration of type IV collagen 7S domain and hepatic failure following resection of hepatocellular carcinoma. Ann Surg 2004;239:186-93.

Sakugawa H, Nakayoshi T, Kobashigawa K, Yamashiro T, Maeshiro T, Miyagi S, et al. Clinical usefulness of biochemical markers of liver fibrosis in patients with nonalcoholic fatty liver disease. World J Gastroenterol 2005;11:255-9.

Li CH, Piao DM, Xu WX, Yin ZR, Jin JS, Shen ZS. Morphological and serum hyaluronic acid, laminin and type IV collagen changes in dimethylnitrosamine-induced hepatic fibrosis of rats. World J Gastroenterol 2005;11:7620-4

Surapaneni KM, Saraswathi P, Shyama S, Subramaniam S. Type IV collagen: a non invasive bio marker to detect non-alcoholic steato hepatitis (NASH), among non-alcoholic fatty liver disease (NAFLD) patients. J Clin Diagnos Res 2010;4:2483-8.

Dos Santos VM, Leite-Mór MMB, Kondo M, Martins JR, Nader H, Lanzoni VP, et al. Serum laminin, type IV collagen and hyaluronan as fibrosis markers in non–alcoholic fatty liver disease. Brazilian J Med Biol Res 2005;38:747–53.

Poynard T, Ratziu V, Naveau S. The diagnostic value of biomarkers (SteatoTest) for the prediction of liver steatosis. Comp Hepatol 2005;4:10.


Refbacks

  • There are currently no refbacks.


Copyright (c) 2016 Universa Medicina



Creative Commons License
Universa Medicina by Faculty of Medicine, Trisakti University is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Based on a work at https://univmed.org/ejurnal/index.php/medicina/